The Study Achieved Its Primary and Secondary Objectives.1
Adapted from Bonten MJM, et al. 2015.
Primary and Secondary Objectives1
Adapted from Bonten MJM, et al. 2015.
The study clearly demonstrated significant reductions in pneumococcal VT-CAP and VT-IPD in adults aged 65 years and older. There were 45.56% fewer first episodes of VT-CAP among PCV13-vaccinated subjects than in subjects who received placebo (P = 0.0006). Additionally, compared with the placebo group, the PCV13 group experienced 45.00% fewer first episodes of VT-NB/NI CAP (P = 0.0067) and 75.00% fewer first episodes of VT-IPD (P = 0.0005). The safety results are depicted below.
Safety Results
Most local reactions and systemic events were mild or moderate in severity. Safety profile of PCV13 in this study was consistent with that observed in previous studies of PCV13 in adults.
CAP, community-acquired pneumonia; CI, confidence interval; IPD, invasive pneumococcal disease; NB/NI, non-bacteraemic/non-invasive; PCV13, 13-valent pneumococcal conjugate vaccine; VE, vaccine efficiency; VT, vaccine type; VT-CAP, vaccine-type community-acquired pneumonia; VT-IPD, vaccine-type invasive pneumococcal disease.
Reference:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
FAQs related to different fields
Learn more
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.